Chronic myeloid leukemia treatment guidelines: Brazilian Association of Hematology, Hemotherapy and Cell Therapy. Brazilian Medical Association Guidelines Project – 2012 Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND Imatinib AND (Time factors OR early OR late OR delay*) AND Therapy/broad[filter])) OR ((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND Imatinib AND (Time factors OR early OR late) AND Prognosis/broad[filter])))) OR (((((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic)) AND Imatinib)) AND therapy/narrow[filter]) PICO 9 Does the cytogenetic evaluation have an impact on prognosis? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis OR Cytogenetic*) AND ((sensitiv*[Title/Abstract] OR sensitivity and specificity[MeSH Terms] OR diagnos*[Title/ Abstract] OR diagnosis[MeSH:noexp] OR diagnostic *[MeSH:noexp] OR diagnosis, differential[MeSH:noexp] OR diagnosis[Subheading:noexp]) OR (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract])) OR (evaluation study OR comparative study OR epidemiologic methods)) PICO 10 Does molecular evaluation by quantitative real time polymerase chain reaction (PCR) have an impact on prognosis? ((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic Rev Bras Hematol Hemoter. 2012;34(5):367-82 OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Polymerase Chain Reaction OR PCR OR Nested PCR OR Anchored PCR) AND molecular AND (prognos*[Title/Abstract] OR (first[Title/Abstract] AND episode[Title/Abstract]) OR cohort[Title/Abstract])) PICO 11 Can cytogenetics be replaced by quantitative PCR (qPCR) to monitor CML patients taking tyrosine kinase inhibitors who attained complete cytogenetic response? ((Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (Cytogenetic Analysis OR Cytogenetic*)) AND (Polymerase Chain Reaction OR PCR OR Nested PCR OR Anchored PCR OR DNA Mutational Analysis) PICO 12 What is the treatment of choice for chronic-phase CML patients resistant to Imatinib 400 mg? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND imatinib AND ((clinical[Title/ Abstract] AND trial[Title/Abstract]) OR clinical trials[MeSH Terms] OR clinical trial[Publication Type] OR random*[Title/ Abstract] OR random allocation[MeSH Terms] OR therapeutic use[MeSH Subheading]) AND drug resistance PICO 13 Are there differences in the toxicity profiles of second- generation tyrosine kinase inhibitors (dasatinib and nilotinib)? (Leukemia, Myelogenous, Chronic, BCR-ABL Positive OR Leukemia, Myeloid, Philadelphia-Positive OR Leukemia, Granulocytic, Chronic OR Myeloid Leukemia, Chronic OR Chronic Myeloid Leukemia OR Leukemia, Myelocytic, Chronic OR Chronic Myelocytic Leukemia OR Leukemia, Myelogenous, Chronic OR Myelogenous Leukemia, Ph1-Positive OR Leukemia, Myeloid, Ph1 Positive OR Myelogenous Leukemia, Chronic OR Myeloid Leukemia, Philadelphia-Positive OR Granulocytic Leukemia, Chronic) AND (dasatinib) AND (nilotinib) AND (adverse effects OR complications OR safety OR toxicity) AND (Therapy/broad[filter] OR comparative study OR epidemiologic methods OR systematic[sb]) 381